Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.


BACKGROUND Many children with asthma continue to experience symptoms despite available therapies. OBJECTIVE This study evaluated the efficacy and safety of omalizumab, a humanized anti-IgE mAb, in children with moderate-to-severe persistent allergic (IgE-mediated) asthma that was inadequately controlled despite treatment with medium-dose or high-dose… (More)
DOI: 10.1016/j.jaci.2009.09.021


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.